VKTX Stock Analysis & IQ Rating | Viking Therapeutics

 Upgraded on attractively valued

 Trading below its fair value

 Earnings are forecast to grow

 Investors confidence is positive

Viking Therapeutics Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know. Viking Therapeutics Inc. (VKTX) reached $31.86 at the closing of the latest trading day reflecting a -7.21% change compared to its last close.

Today

Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook. We recently published 10 Big Names Delivering Outsized Gains. Viking Therapeutics Inc. (NASDAQ:VKTX) was one of the top performers on Wednesday. Viking Therapeutics grew its share prices by 11.89 percent on Wednesday to finish at $34.34 apiece as investors took heart from comments that the weight loss industry appears larger than visible sparking robust prospects [….]

Today

VKTX Crosses Below Key Moving Average Level. In trading on Tuesday shares of Viking Therapeutics Inc (Symbol: VKTX) crossed below their 200 day moving average of $30.56 changing hands as low as $29.54 per share. Viking Therapeutics Inc shares are currently trading down about 5.5% on the day. The chart below shows the o

Tue Jan 13, 2026

Viking Therapeutics Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.

Tue Jan 13, 2026

Notable Monday Option Activity: VKTX UAL AGYS. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Viking Therapeutics Inc (Symbol: VKTX) where a total volume of 12410 contracts has been traded thus far today a contract volume which is representative of app

Mon Jan 12, 2026

VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug. Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735 testing flexible oral and injectable dosing after initial weight loss in obese adults.

Fri Jan 9, 2026

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet. Based on the average brokerage recommendation (ABR) Viking Therapeutics (VKTX) should be added to ones portfolio. Wall Street analysts overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So is the stock worth buying?

Thu Jan 8, 2026

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer. Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise) a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders today announced the appointment of ".As we continue to advance our promising portfolio of metabolic therapies including VK2735 our potentially best-in-class GLP-1Prior to

Wed Jan 7, 2026

Heres How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today. Viking Therapeutics (NASDAQ:) has outperformed the market over the past 10 years by 15.18% on an annualized basis producing an average annual return of 28.75%. Currently Viking Therapeutics has a market capitalization of $3.66 billion.

Tue Jan 6, 2026

Viking Therapeutics Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note. In the closing of the recent trading day Viking Therapeutics Inc. (VKTX) stood at $32.12 denoting a -9.32% move from the preceding trading day.

Mon Jan 5, 2026